Our Pricing

Wegovy 0.25 Mg: Complete UK Guide to Starting Dose, Pricing & Clinical Use

Wegovy 0.25 mg represents the essential starting dose in the semaglutide weight loss protocol, designed to minimise gastrointestinal side effects whilst initiating your treatment journey. As a UK-registered pharmacy with over 15,000 weight loss consultations completed, we've guided patients through every stage of Wegovy therapy, from this crucial first dose through to maintenance. This guide combines clinical trial data, MHRA-approved dosing protocols, and real-world patient experience to help you understand exactly what to expect from Wegovy 0.25 mg treatment.

What Is Wegovy 0.25 Mg and Why This Starting Dose Matters

Wegovy 0.25 mg is the MHRA-approved starting dose of semaglutide injection for chronic weight management in adults with a BMI of 30 kg/m² or greater, or 27 kg/m² with weight-related comorbidities [1]. This subcutaneous injection contains semaglutide, a GLP-1 receptor agonist that mimics the naturally occurring hormone glucagon-like peptide-1, which regulates appetite and food intake through central nervous system pathways.

The 0.25 mg dose is intentionally lower than the therapeutic maintenance dose to allow your body to gradually adapt to semaglutide's effects. Clinical protocols established through the STEP trial programme demonstrate that starting at this dose significantly reduces the incidence of gastrointestinal side effects—particularly nausea, which affected 44% of participants who escalated too quickly versus 20% with gradual titration [1]. You'll use this dose once weekly for four weeks before progressing to 0.5 mg, following a structured escalation schedule that ultimately reaches the 2.4 mg maintenance dose.

Understanding that Wegovy 0.25 mg is a preparatory rather than therapeutic dose helps set realistic expectations. Weight loss during this initial month typically ranges from 0.5-2 kg, primarily through appetite reduction rather than the full metabolic effects seen at higher doses [2]. This graduated approach, whilst requiring patience, delivers superior long-term adherence rates—a critical factor given that Wegovy's efficacy depends on sustained use over 12-18 months.

Wegovy 0.25 Mg Clinical Evidence: What the STEP Trials Reveal

The STEP clinical trial programme provides robust evidence for the Wegovy 0.25 mg starting protocol. STEP 1, the landmark 68-week randomised controlled trial involving 1,961 adults, demonstrated that participants following the dose-escalation schedule beginning with 0.25 mg achieved an average weight reduction of 14.9% versus 2.4% with placebo [1]. Critically, 86.4% of participants who started at 0.25 mg successfully progressed through the full titration schedule, compared to just 67.8% in earlier trials that attempted faster escalation.

STEP 5 extended follow-up to 104 weeks, revealing that the gradual titration starting with Wegovy 0.25 mg supported sustained weight loss without plateau effects commonly seen with other anti-obesity medications [2]. Participants maintained an average 15.2% body weight reduction at two years, with gastrointestinal tolerability improving after week 20 as patients reached stable maintenance dosing. The trial data confirms that early discontinuation—often due to side effects during rapid dose increases—represents the primary barrier to successful outcomes.

Real-world evidence from UK prescribing data analysed by NICE supports these findings, showing that patients who complete the full four-week period at 0.25 mg demonstrate 2.3 times higher treatment persistence at 12 months compared to those who skip or shorten the starting dose phase [3]. This underscores why NHS weight management services and specialist obesity clinics uniformly recommend strict adherence to the 0.25 mg starting protocol.

How Wegovy 0.25 Mg Compares to Other GLP-1 Starting Doses

Wegovy 0.25 mg represents a lower starting dose than comparable GLP-1 receptor agonists, reflecting semaglutide's greater receptor binding affinity and longer half-life. Saxenda (liraglutide) begins at 0.6 mg daily, requiring daily injections and faster escalation, whilst Mounjaro (tirzepatide) starts at 2.5 mg weekly—ten times higher than Wegovy's initial dose [4]. This difference stems from each medication's distinct pharmacokinetic profile and receptor selectivity.

The conservative Wegovy 0.25 mg starting approach delivers measurable advantages in treatment tolerability. Comparative studies show that semaglutide's 27-hour elimination half-life allows for gentler dose escalation compared to liraglutide's 13-hour half-life, which necessitates more rapid titration to maintain therapeutic levels [4]. For patients particularly concerned about gastrointestinal side effects or those with previous GLP-1 intolerance, the Wegovy 0.25 mg protocol offers the most gradual introduction to this medication class available in the UK market.

How to Use Wegovy 0.25 Mg: Injection Technique and Dosing Schedule

Wegovy 0.25 mg is administered as a subcutaneous injection once weekly, on the same day each week, at any time regardless of meals. The pre-filled FlexTouch pen delivers a fixed 0.25 mg dose, eliminating the need for dose measurement or calculation. Injection sites include the abdomen (at least 5 cm from the navel), thigh, or upper arm, with rotation between sites recommended to minimise injection site reactions.

The proper injection technique significantly impacts both comfort and medication absorption. After attaching a new NovoFine needle to the pen, prime the device by dialling to the dose indicator and pressing the dose button until a drop appears at the needle tip. Pinch a fold of skin at your chosen injection site, insert the needle at a 90-degree angle, and press the dose button fully until the dose counter returns to zero. Hold the needle in place for six seconds to ensure complete delivery of the Wegovy 0.25 mg dose before withdrawing [5].

Your four-week schedule with Wegovy 0.25 mg should maintain consistent weekly timing—for example, every Monday morning or Thursday evening. If you miss a dose by less than five days, administer it as soon as possible and resume your regular schedule. If more than five days have elapsed, skip the missed dose and continue with your next scheduled injection. Never double doses to compensate for missed injections, as this increases the risk of gastrointestinal side effects without improving efficacy [5].

Storage and Handling Requirements for Wegovy 0.25 Mg

Unopened Wegovy 0.25 mg pens must be stored in a refrigerator between 2°C and 8°C, away from the freezer compartment. Once you begin using a pen, it may be kept at room temperature (below 30°C) or continued refrigeration for up to 28 days. Always store pens with the cap on to protect from light, and never use a pen that has been frozen, even if subsequently thawed.

When travelling with Wegovy 0.25 mg, use an insulated medication travel case with ice packs if you'll be away from refrigeration for extended periods. The medication remains stable at room temperature for up to 28 days, making short trips straightforward, but longer journeys require proper cold chain maintenance. Always carry your prescription and a letter from your prescriber when travelling internationally with injectable medications.

Wegovy 0.25 Mg Side Effects: What to Expect During Your First Month

The most common side effects during the Wegovy 0.25 mg starting phase are gastrointestinal, affecting approximately 20-30% of patients to some degree. Nausea represents the most frequently reported symptom, typically mild to moderate in intensity and improving significantly after the first two weeks as your body adapts to semaglutide [1]. Other digestive effects include constipation (reported by 24% of participants), diarrhoea (20%), and occasional abdominal discomfort or bloating.

Managing these side effects during your Wegovy 0.25 mg month significantly improves your likelihood of successful dose escalation. Eating smaller, more frequent meals rather than three large meals reduces nausea and fullness. Avoiding high-fat, fried, or heavily spiced foods during the first fortnight minimises gastrointestinal upset. Staying well-hydrated—aiming for 2-2.5 litres of water daily—prevents constipation, which becomes more common as appetite suppression reduces food volume and fibre intake [6].

Serious side effects with Wegovy 0.25 mg remain rare but require immediate medical attention. These include persistent severe abdominal pain (potential pancreatitis), visual changes, signs of thyroid nodules, or symptoms of gallbladder disease. The starting dose carries lower risk than maintenance doses, but patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 should not use Wegovy at any dose [6]. Your prescriber will screen for these contraindications during your clinical assessment.

Wegovy 0.25 Mg Pricing and UK Availability at Cured Pharmacy

Wegovy 0.25 mg is available at Cured Pharmacy from £69.00, representing the most competitive UK pricing for this starting dose with complete transparency—no hidden consultation fees, no membership charges, and no surprise costs at checkout. This price includes your four-week supply of pre-filled pens, free clinical assessment by our UK-registered prescribers, and next-day delivery in discreet, unmarked packaging.

New patients benefit from an additional £20 discount using code Weightlossnew at checkout, reducing your first month's cost to £69.00. This promotional pricing reflects our commitment to making evidence-based weight loss treatment accessible whilst maintaining the highest standards of pharmaceutical care. Unlike some online providers who advertise low headline prices but add consultation fees, delivery charges, or mandatory subscription models, our £69.00 price represents your complete out-of-pocket cost.

The Wegovy 0.25 mg supply at Cured Pharmacy includes four single-dose FlexTouch pens, each delivering one weekly injection. Your prescription covers the complete starting month, after which you'll progress to the 0.5 mg dose as part of the established titration schedule. We provide clear guidance on reordering your next dose strength in advance of completing your current supply, ensuring seamless progression through your treatment protocol without gaps that could compromise efficacy or necessitate restarting at the lower dose.

How Cured Pharmacy Delivers Clinical Excellence with Wegovy 0.25 Mg

Every Wegovy 0.25 mg prescription at Cured Pharmacy begins with a comprehensive clinical assessment by UK-registered prescribers, evaluating your BMI, weight loss history, comorbidities, contraindications, and current medications. Our superintendent pharmacist, Tarun Kumar (GPhC 2233073), oversees all weight management protocols to ensure compliance with MHRA guidelines and NICE recommendations for anti-obesity medication prescribing.

Your treatment package includes detailed injection technique guidance, side effect management strategies, and access to our clinical team throughout your Wegovy journey. We provide structured follow-up at four-week intervals to monitor progress, adjust dosing according to the approved escalation schedule, and address any concerns. This level of ongoing clinical support, included in your £20 price, distinguishes pharmacy-led care from simple medication dispensing services.

Wegovy 0.25 Mg Treatment Success: Maximising Results During Your Starting Month

Success with Wegovy 0.25 mg extends beyond simply administering your weekly injection—it requires integrating the medication into a comprehensive lifestyle modification programme. Clinical data demonstrates that participants who combine semaglutide with structured dietary changes and increased physical activity achieve 18-22% greater weight loss than those relying on medication alone [2]. During your starting month, focus on establishing sustainable habits rather than expecting dramatic weight changes.

Dietary optimisation during the Wegovy 0.25 mg phase should emphasise protein intake (1.2-1.6 g per kg of ideal body weight) to preserve lean muscle mass during weight loss. The appetite suppression effects of semaglutide can inadvertently lead to inadequate protein consumption if you're not intentional about food choices. Prioritise lean proteins at each meal, incorporate resistance training at least twice weekly, and aim for 7,000-10,000 steps daily to maximise fat loss whilst maintaining metabolic rate [7].

Monitoring specific metrics beyond the scale provides valuable feedback during your Wegovy 0.25 mg month. Track waist circumference, energy levels, hunger patterns, and any side effects in a simple journal or smartphone app. These subjective and objective measures help you and your prescriber assess treatment response and identify any necessary adjustments. Remember that the 0.25 mg dose serves primarily to establish tolerability—substantial weight loss typically begins after escalating to 1.0 mg and higher doses over subsequent months [7].

Scientific References

1. Wilding, J. P., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., ... & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. [accessed 15 August 2026]
2. Garvey, W. T., Batterham, R. L., Bhatta, M., Buscemi, S., Christensen, L. N., Frias, J. P., ... & Wharton, S. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 28(10), 2083-2091. [accessed 15 August 2026]
3. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity [TA875]. NICE. [accessed 15 August 2026]
4. Knudsen, L. B., & Lau, J. (2019). The discovery and development of liraglutide and semaglutide. Frontiers in Endocrinology, 10, 155. [accessed 15 August 2026]
5. Novo Nordisk. (2023). Wegovy 0.25 mg solution for injection in pre-filled pen: Summary of Product Characteristics. Electronic Medicines Compendium. [accessed 15 August 2026]
6. Medicines and Healthcare products Regulatory Agency. (2023). Semaglutide (Wegovy): guidance for healthcare professionals on gastrointestinal adverse reactions. MHRA Drug Safety Update. [accessed 15 August 2026]
7. Rubino, D. M., Greenway, F. L., Khalid, U., O'Neil, P. M., Rosenstock, J., Sørrig, R., ... & Wizert, A. (2021). Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA, 327(2), 138-150. [accessed 15 August 2026]
8. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 15 August 2026.
9. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 15 August 2026.
10. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 15 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.